Brief: Pepgen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For Pgn-Edo51 To Treat A Muscle Disorder

PepGen

13/03/2024 12:38

March 13 (Reuters) - PepGen Inc  PEPG.O :
    * PEPGEN RECEIVES U.S. FDA ORPHAN DRUG AND RARE PEDIATRIC
DISEASE
DESIGNATIONS FOR PGN-EDO51 FOR THE TREATMENT OF DUCHENNE
MUSCULAR DYSTROPHY
    * PEPGEN INC -EXPECTS TO BEGIN ENROLLING PATIENTS IN
CONNECT2
PHASE 2 TRIAL LATER THIS YEAR

Source text for Eikon:  ID:nGNX2qZ308 
Further company coverage:  PEPG.O 

 ((Reuters.Briefs@thomsonreuters.com;))